Zydus Cadila launches India's 'cheapest' remdesivir at Rs 2,800 per vial

Zydus is the fifth company to launch a copy of the antiviral in India after privately held Hetero Labs Ltd, Cipla, Mylan NV and Jubilant Life Sciences Ltd

coronavirus, coronavirus vaccine
It will be sold under the brand name Remdac to government and private hospitals treating Covid-19 patients, the company said in a regulatory filing
Reuters Bengaluru
1 min read Last Updated : Aug 13 2020 | 11:10 AM IST
 Zydus Cadila on Thursday launched the cheapest generic version of Gilead Sciences' antiviral drug remdesivir in India to treat Covid-19 following reports of shortages at hospitals in the world's third-worst hit nation.

Zydus has priced it at Rs 2,800 ($37.44) per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating Covid-19 patients, the company said in a regulatory filing.

Officials in some Indian states had a few weeks ago complained of supply issues, but a top executive at drugmaker Cipla Ltd had earlier this week said the supplies were stabilising.

Zydus is the fifth company to launch a copy of the antiviral in India after privately held Hetero Labs Ltd, Cipla, Mylan NV and Jubilant Life Sciences Ltd.

Gilead has also entered into licensing agreements with Dr.Reddy's Laboratories Ltd and Syngene International Ltd to make remdesivir for distribution in 127 countries, including India.

India has reported a daily jump of more than 50,000 coronavirus infections for two weeks, with total cases as of Wednesday at 2.33 million.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Coronavirus VaccineCoronavirus TestsZydus PharmaceuticalsZydus Cadila

Next Story